Oscar Miranda is a dynamic and accomplished Biopharmaceutical Scientist and Biomedical Engineer, currently serving as the Director of Preclinical Therapeutics Genes Product Development at CodeBridgeBio Inc. In this pivotal role, Oscar leverages his extensive expertise in drug delivery technologies and preclinical studies to spearhead innovative...
Oscar Miranda is a dynamic and accomplished Biopharmaceutical Scientist and Biomedical Engineer, currently serving as the Director of Preclinical Therapeutics Genes Product Development at CodeBridgeBio Inc. In this pivotal role, Oscar leverages his extensive expertise in drug delivery technologies and preclinical studies to spearhead innovative projects that harness cutting-edge platforms such as RNA interference (RNAi), messenger RNA (mRNA), CRISPR-Cas gene editing, CAR T-cell engineering, and the development of peptides and small molecules. His leadership in these areas is instrumental in advancing the company’s mission to deliver transformative therapies that address unmet medical needs.
Oscar's current projects focus on the integration of these advanced technologies to create novel therapeutic solutions that enhance patient outcomes. His work in RNAi and mRNA platforms aims to develop targeted gene silencing and protein expression therapies that can effectively combat a range of diseases. Additionally, his expertise in CRISPR-Cas technology positions CodeBridgeBio at the forefront of gene editing innovations, enabling precise modifications that can lead to groundbreaking treatments.
With a strong foundation in data integrity and problem-solving, Oscar excels in product planning and launch experience, ensuring that each project is meticulously executed from concept to delivery. His proficiency in cell culture and surface modification techniques further enhances the development of robust therapeutic candidates. As a co-founder of a biomedical startup, Oscar embodies the entrepreneurial spirit necessary to drive forward-thinking initiatives in the biopharmaceutical landscape. His commitment to excellence and innovation continues to make a significant impact in the field, positioning CodeBridgeBio as a leader in preclinical therapeutic development.
